Stem Cell Clinic

NK Cell Therapy and Stem Cell Therapy Market 2020-26, Research Report Covers Updated Data Considering Impact of Covid-19 on Share, Size and Future…

By adminJuly 18, 2020Stell Cell Research

NK Cell Therapy and Stem Cell Therapy Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global NK Cell Therapy and Stem Cell Therapy Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.

Report Overview: This report covers an analysis of the global NK Cell Therapy and Stem Cell Therapy Market for the forecast period 2020-2026. It unravels that the market is set to register steady growth rate in the coming years. The valuation of the global market is covered for facilitating a comparative study of the past and future data. It also offers a detailed segmental assessment of the market based on different parameters.

Leading Key Players: Chipscreen Biosciences Innate Pharma SA Osiris Therapeutics Chiesi Pharmaceuticals Molmed JCR Pharmaceutical Altor BioScience Corporation Affimed NV Takeda Pharmaceutical Pharmicell Medi-post NuVasive Anterogen

This analysis includes a detailed share analysis of the key players. It also unveils the growth trajectories of the NK Cell Therapy and Stem Cell Therapy Market participants along with their current statuses and key developments. The growth strategies employed by these players are also assessed in the report and are prognosticated to facilitate study of the competitive landscape of the global Artificial Heart Valve Market.

Get Free Sample [emailprotected] https://www.algororeports.com/sample-request/nk-cell-therapy-and-stem-cell-therapy-market-research-report-trends-one-2940079?utm_source=3wnews&utm_medium=53

Drivers and Restraints: The factors that are supposed to lead the expansion of the global market are highlighted in the assessment. The market factors are assessed and analyzed to understand their impact on the growth curve. Similarly, the factors that are presumed to restrain the growth of the market are also studied in the report.

Regional Analysis: The regions covered for the evaluation of the global NK Cell Therapy and Stem Cell Therapy Market are

North America (Covered in Chapter 6 and 13) United States Canada Mexico Europe (Covered in Chapter 7 and 13) Germany UK France Italy Spain Russia Others Asia-Pacific (Covered in Chapter 8 and 13) China Japan South Korea Australia India Southeast Asia Others Middle East and Africa (Covered in Chapter 9 and 13) Saudi Arabia UAE Egypt Nigeria South Africa Others South America (Covered in Chapter 10 and 13) Brazil Argentina Columbia Chile Others

The analysis of these regional segment is followed by a country-level analysis of each for every region. A comparative study of the segments is offered with the inclusion of valuation for every segment on both country and regional level.

Method of Research: The assessment leverages advanced and robust methodologies to provide fact-based actionable insight into the market. Key market divergences are analyzed in the report for deriving accurate information regarding the growth trajectory of the market. These market divergences identified in the research process are current status of the market, ongoing industry trends, past data, latest developments, etc. Cutting-edge data analytical tools are employed for the filtration, validation, and authentication of data collected from primary and secondary research sources. The inputs are collected from credible sources, including but not limited to, paid database services, interviews with stakeholders across the value chain (MDs, CEOs, VPs,etc.), SEC filings, surveys, and whitepaper references among others. Zero deviation from facts is ensured with the utilization of a multi-layer verification process. It also assures adherence to the highest standards of data mapping and value extrapolation. Top-down and bottom-up approaches are executed to authenticate the accuracy of the quantitative data provided in the report.

CONTENTS

ENQUIREY TO BUY REPORT@ https://www.algororeports.com/enquiry/nk-cell-therapy-and-stem-cell-therapy-market-research-report-trends-one-2940079?utm_source=3wnews&utm_medium=53

About Us:

AlgoroReportsis one of the most significant database of online market researches and intelligence reports and services. The online portal for marketing research deals with access to global market data and assists in providing expert insights and exposure on global companies, industries, products and trends. AlgoroReports Consists of a highly motivated team of young and experienced individual focused on providing clients expert information they need.

Sanjay Jain

Manager Partner Relations & International Marketing

Website: https://www.algororeports.com/

Ph: +1-352-353-0818 (US)

See the rest here:
NK Cell Therapy and Stem Cell Therapy Market 2020-26, Research Report Covers Updated Data Considering Impact of Covid-19 on Share, Size and Future...

Induced Pluripotent Stem Cell Market 2019 by Rising-Trends, Growth Analysis, Industry Share, Product Types, User-Demand, Business Strategy and…

By adminJuly 18, 2020Stell Cell Research

The global Induced Pluripotent Stem Cell market is forecasted to reach a market value of ~US$ XX Mn/Bn by the end of 2029 registering a CAGR growth of around XX% during the forecast period (2019-2029). The recent market report provides a detailed analysis of the current structure of the Induced Pluripotent Stem Cell market along with the estimated trajectory of the market over the course of the stipulated timeframe.

The report provides an in-depth assessment of the numerous factors that are anticipated to impact the market dynamics with utmost precision and accuracy. The SWOT and Porters Five Forces Analysis provides a clear picture about the current operations of the various market players operating in the global Induced Pluripotent Stem Cell market.

Request Sample Report @https://www.mrrse.com/sample/16525?source=atm

The Induced Pluripotent Stem Cell market report portrays the market share and the application of each of the sub-segments across various verticals.

The Induced Pluripotent Stem Cell market report explains how the Induced Pluripotent Stem Cell is being deployed in different sector.

Competitive landscape:

The report ponders over the market scenario in various geographies and highlights the major opportunities, trends, and challenges faced by market players in each region. An in-depth country wise analysis of each major region provides readers a deep understanding of the regional aspects of the market including, the market share, pricing analysis, revenue growth, and more.

Market Taxonomy

The global iPS cell market has been segmented into:

Cell Type

Application

End User

Region

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16525?source=atm

The market report on the Induced Pluripotent Stem Cell market addresses some important questions such as:

Crucial data enclosed in the report:

Buy This Report @ https://www.mrrse.com/checkout/16525?source=atm

Felipe Massa gives rare insight into Michael Schumachers condition and recovery – Mirror Online

By adminJuly 18, 2020Stem Cell Doctors

Michael Schumacher is one of the greatest racing drivers to have ever lived.

But in 2014 he suffered a devastating skiing accident that has kept him out of the public eye ever since.

With a record breaking seven championship wins to his name, five of them consectively, Schumacher has roared to victory more times than any other driver.

After starting karting as a child, the 51-year-old worked his way up to Formula One, spending most of his career driving for Mercedes.

However, he did switch to Ferrari in 1996, who had last won the championship in 1979, and transformed them into one of the most successful teams in the sport.

Even after he retired in 2006, he couldn't get the sport out of his blood and returned to the track just four years later.

Two years later he announced his career as a racing driver really was over for good and Britain's Lewis Hamilton replaced him at Mercedes.

In an emotional speech announcing his decision, Schumacher said while he still felt "able to compete with the best drivers" he wasn't sure if he had the "motivation and energy which is necessary to go on".

Just over a year after he announced his retirement, on December 29, 2013, while skiing with his then 14-year-old son, Mick, Schumacher suffered a devastating accident.

The father and son was skiing down the Combe de Saulire above Meribel in the French Alps.

It was while they were crossing an unsecured off-piste area that Schumacher, an accomplished skiier, fell and hit his head on a rock.

His life was saved by his ski helmet and the racing legend was airlifted to hospital and underwent two operations to save him.

Schumacher was placed in a medically induced coma and his doctors said his condition was stable.

By June the following year, it was reported that Schumacher had regained consciousness and he was transferred to a hospital for rehab.

He was allowed home in September of that year, where his rehab has continued, but where updates about his condition have been few and far between.

His devoted wife, Corinna, and management team have always insisted his health is a private issue and have remained tight-lipped about what, if any, progress the racing legend has made since his injury.

In a rare update just before the sixth anniversary of Schumacher's devastating accident, Corrina said "big things start with small steps".

Then, in January this year, a neurosurgeon has claimed Schumacher's condition has "deteriorated" since the accident just over six six years ago.

Nicola Acciari said: "We must imagine a person very different from the one we remember on the track, with a very altered and deteriorated organic, muscular and skeletal structure,

"All as a result of the brain trauma he suffered."

Back in May, Schumacher's team-mate at Ferrari, Felipe Massa, gave a rare update into the champion's condition.

He said: "I know how he is, I have information. The main thing about all this is that we know his situation is not easy. He is in a difficult phase but we need to respect him and the family."

There finally seemed to be a glimmer of hope when reports last month claimed the F1 ace was to undergo stem cell surgery within days.

It gave hope to Schumacher's fans around the world but just days later the claims seemed to be false.

While his family maintained their silence they are thought to have not even considered the procedure during the coronavirus pandemic.

However, six years after his accident, the racing great is believed to have been left with devastating health complications because he has been confined to his bed for so long.

He is reported to now be suffering from muscle atrophy, which has caused his muscles to waste away and osteoporosis, which weakens bones.

It had been hoped the stem cell surgery would regenerate Schumacher's nervous system and would be carried out by French cardiologist Dr Philippe Menasche.

The doctor has previously managed to graft healthy stems cells onto the heart by replacing damaged ones with a healthy replacement.

While the surgery is deemed to be safe there is currently no evidence as to what impact it would have on the brain.

COVID-19 UPDATE : Global Human Embryonic Stem Cell Market 2020 Comprehensive Study with Arizona Board of Regents, STEMCELL Technologies Inc, Cellular…

By adminJuly 18, 2020Embryonic Stem Cells

The Global Human Embryonic Stem Cell Market report demonstrates supportive data related to the dominant players in the market such as product offerings, revenue, segmentation, and business synopsis. The report gives helpful insights which assist while launching a new product. This global market research report has complete overview of the market, covering various aspects such as product definition, segmentation based on various parameters, and the prevailing vendor landscape. Moreover, in the Global Human Embryonic Stem Cell Market report, the key product categories are also included. The report also analyses the emerging trends along with major drivers, challenges and opportunities in the Global Human Embryonic Stem Cell Market.

The Global Human Embryonic Stem Cell Market study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. To understand the competitive landscape in the market, an analysis of Porters five forces model for the market has also been included. Furthermore, businesses can decide upon the strategies about the product, customer, key player, sales, promotion or marketing by acquiring a detailed analysis of competitive markets. The Global Human Embryonic Stem Cell Market report is a synopsis about how is the market status right now and how will it be in the forecast years for industry.

Human embryonic stem cell market estimated to register a healthy CAGR of 10.5% in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the increase in tissue engineering process.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-human-embryonic-stem-cell-market

Key Market Competitors:

Some of the major companies functioning in global human embryonic stem cell market are Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc, Waisman Biomanufacturing, Caladrius, Pfizer Inc., Thermo Fisher Scientific, Merck KGaA, Novo Nordisk A/S, Johnson & Johnson Services, Inc and SA Biosciences Corporation among others.

Global Human Embryonic Stem Cell Market By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells), Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), End User (Research, Clinical Trials, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Key Developments in the Market:

In January 2019, STEMCELL Technologies, launched mTeSR Plus, a Next-generation culture system for human embryo system and IPS cell maintenance. This launch will able to promote more consistent cell culture environment through sustained medium pH and stabilized components In January, 2018 Mayo Foundation for Medical Education and Research, got approval on the tool named as automated bioreactor. This tool can manufacture the stem cells, in billions within a day. This will allow the company to harvest the cell from bone marrow, this will allow the treatment of patients when their own cell is not in use, which will allow the Mayo Clinic to accelerate its existing studies using stem cells

Market Definition: Global Human Embryonic Stem Cell Market

Human embryonic stem cell is pluripotent stem cells, derivative of inner cell of blastocyst from inner cell mass of embryo. Embryonic stem cell gives rise to somatic cells in embryo. This is a useful tool to understand the difficult process mechanism involved in growth of specialized cells and establishment of organ structures, which are alternative to cancer therapy.

Market Drivers

Increase prevalence of cardiac and malignant diseases is driving the market growth Growing R&D investments and research initiatives which will propel the market in the forecast period High requirement for regenerative medicines is acting as a catalyst for growth of the market Support from government in funding and regulation can also boost the market growth

Market Restraints

Costly procedures and regulatory complications is acting as a restraint for the market growth Strict regulatory guidelines is hindering the growth of the market Ethical and policy concern may hamper the market in the forecast period

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

Table of Contents-Snapshot Executive Summary Chapter 1 Industry Overview Chapter 2 Industry Competition by Manufacturers Chapter 3 Industry Production Market Share by Regions Chapter 4 Industry Consumption by Regions Chapter 5 Industry Production, Revenue, Price Trend by Type Chapter 6 Industry Analysis by Applications Chapter 7 Company Profiles and Key Figures in Industry Business Chapter 8 Industry Manufacturing Cost Analysis Chapter 9 Marketing Channel, Distributors and Customers Chapter 10 Market Dynamics Chapter 11 Industry Forecast Chapter 12 Research Findings and Conclusion Chapter 13 Methodology and Data Source.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

The current trend pertaining to the demand supply and sales together with the recent developments have been given here to provide an exhaustive picture of this market. It also allows voluntarily accessible affordable reports of the research that is the end result of the personalized research carried by the internal team of professionals.

To comprehend Global Human Embryonic Stem Cell market dynamics in the world mainly, the worldwide Human Embryonic Stem Cell market is analyzed across major global regions.

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Segmentation: Global Human Embryonic Stem Cell Market

By Type

Totipotent Stem Cells Pluripotent Stem Cells Unipotent Stem Cells

By Application

Regenerative Medicine Stem Cell Biology Research Tissue Engineering Toxicology Testing

By End User

Research Clinical Trials Others

Reasons to Purchase this Report

Current and future of global human embryonic stem cell market outlook in the developed and emerging markets The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period Regions/Countries that are expected to witness the fastest growth rates during the forecast period The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at country level All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

View original post here:
COVID-19 UPDATE : Global Human Embryonic Stem Cell Market 2020 Comprehensive Study with Arizona Board of Regents, STEMCELL Technologies Inc, Cellular...

Cytomegalovirus Treatment Market Research Insights 2019 Global Industry Outlook Shared in Detailed Report, Forecast to 2026 – 3rd Watch News

By adminJuly 17, 2020Stem Cell Treatment

The global Cytomegalovirus Treatment market is forecasted to reach a market value of ~US$ XX Mn/Bn by the end of 2029 registering a CAGR growth of around XX% during the forecast period (2019-2029). The recent market report provides a detailed analysis of the current structure of the Cytomegalovirus Treatment market along with the estimated trajectory of the market over the course of the stipulated timeframe.

Request Sample Report @https://www.mrrse.com/sample/19063?source=atm

The Cytomegalovirus Treatment market report portrays the market share and the application of each of the sub-segments across various verticals.

The Cytomegalovirus Treatment market report explains how the Cytomegalovirus Treatment is being deployed in different sector.

Competitive landscape:

Competitive Assessment

This chapter includes a comprehensive list of all the leading manufacturers in the Cytomegalovirus treatment market, along with detailed information about each company, including company overview, revenue share, strategic overview, and recent company developments. Market players featured in the report include Merck & Co. Inc, Mylan N.V., Chimerix, Inc., Thermo Fisher Scientific, Abbott, Becton, Dickinson and Company, Johnson & Johnson, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pfizer and among others

Chapter 15 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Region

This section highlights Cytomegalovirus treatment in the overall global market by value (US$ Mn) forecast and analysis, by region such as North America, Latin America, Western Europe, Eastern Europe and Asia Pacific Including Japan, China and MEA.

Chapter 16 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Drug Type

Based on drug type market analysis, the Cytomegalovirus treatment market is segmented into Ganciclovir, valganciclovir, Foscarnet, Cidofovir and other.

Chapter 17 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Application

Based on Application, the Cytomegalovirus treatment market is segmented into Stem Cell Transplantation, Organ Transplantation, Congenital CMV infection and others.

Chapter 18 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028 by Distribution Channel

Based on distribution channel, the Cytomegalovirus treatment market is segmented into hospital pharmacies, retail pharmacies, drugstores, and e-Commerce.

Chapter 19 Global Cytomegalovirus Treatment Market Analysis 2013-2017 and Opportunity Assessment 2018-2028

This section highlights the overall global market value (US$ Mn) forecast and analysis of the Cytomegalovirus treatment market, with detailed incremental opportunity and absolute opportunity.

Chapter 20 Assumptions and Acronyms Used

This section consists of a glossary of the assumptions and acronyms used in the Cytomegalovirus treatment market report.

Chapter 21 Research Methodology

This chapter helps readers understand the research methodology that is followed to obtain various conclusions, important qualitative information, and quantitative information about the Cytomegalovirus treatment market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/19063?source=atm

The market report on the Cytomegalovirus Treatment market addresses some important questions such as:

Crucial data enclosed in the report:

Buy This Report @ https://www.mrrse.com/checkout/19063?source=atm

Go here to see the original:
Cytomegalovirus Treatment Market Research Insights 2019 Global Industry Outlook Shared in Detailed Report, Forecast to 2026 - 3rd Watch News

The International Space Station creates bigger, colder states of matter than are possible on Earth – Massive Science

By adminJuly 17, 2020Stem Cell Doctors

Eight years ago, I was packing my home and entire life in Mexico to move to the US to pursue a PhD in Ecology and Evolutionary Biology at the University of California-Irvine. Those were easier times, although it did not seem like it at the time. I spent a few months worth of income to pay for paperwork to apply for an F-1 student visa, and to pay for other documents to enroll as a graduate student. This was after I dedicated months to emailing professors everywhere in the US, hoping that one of them would reply to my email and would invite me to apply to join their lab. It was also after spending time and money paying for standardized tests, official document translations, and application fees. It was a one-and-a-half-year process but in July 2012, I was finally moving to the USA to pursue my PhD. It was a dream come true.

It was also a dream come true for the University of California because I had a full scholarship from my home country that paid for the entirety of my international tuition and fees, which were around $35,000 per year. My scholarship allowed me to pursue my PhD in the USA, and to UC Irvine it provided basically free labor as well as prestige.

I paid taxes and did all of the typical graduate student responsibilities. I also dedicated a lot of my time to doing outreach to bring science to underserved communities around Orange County and Southern California. By the time I graduated in 2017, I was a stellar student, with three publications with UC Irvine's name on them. I co-organized summer science camps for middle school girls that brought money and a good reputation to my university and program. I mentored students of all ages. I was a good citizen of my program, of my university, and of Orange County.

Like me, most international students leave their families and everything that they are comfortable with to pursue the dream of graduate school. They bring with them the hope of being welcomed and treated fairly by their American peers. I have experienced this, but I am one of the lucky ones.

It is no secret that international students and postdocs will withstand abuse and other injustices just so they can keep their visa, which is always tied to their university. Many universities receive international students without having a system to deal with the unique challenges that international students face, such as having no credit history, which complicates finding a place to live and leaves international students vulnerable to landlord abuse. Many international students are people of color, and universities, especially predominantly white institutions, do not have resources to ensure safety of these students within the university and in the community at large.

These challenges are further complicated due to a lack of community and support. Making friends in the US, especially if you are coming from Global South countries and/or non-Westernized countries, is extremely challenging. Many times, I have seen how western Europeans, Australians, and Canadians are rapidly accepted in the local community, while many Latinx, Asians, and Middle-Easterners are not.

There are over one million international students in the US. The ICE Student Ban may no longer be a threat, but universities still need to change how they handle international students. We are people too, but many universities have historically valued us only by the amount of money we bring. We improve higher education not only by the money that we bring, but by our unique perspectives, our research productivity, and our willingness to give back to American society.

See the original post:
The International Space Station creates bigger, colder states of matter than are possible on Earth - Massive Science

Gene Therapy Market Size Is Expected to Grow at a CAGR of 40.7% By 2025 | Share Analysis, Growth Outlook, COVID-19 Impact and Size Estimation -…

By adminJuly 17, 2020Gene Therapy Clinics

(MENAFN - iCrowdNewsWire) Jul 17, 2020

Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo, Others), By Indication (Oncology, Genetic Diseases, Others) and By End-User (Hospitals & Clinics, Specialty Treatment Centers), Forecast to 2025

Gene Therapy Market Landscape

The Gene Therapy Market size in 2018 was valued at USD 524 million. It is likely to grow at a whopping 40.7% CAGR by 2025, as per the Market Research Future's (MRFR) new report. Gene therapy comprises replacing, repressing, and repairing dysfunctional genes that cause disease. The aim of this promising treatment is in re-establishing the normal function. This therapy helps to treat different genetic diseases such as inherited disorders, namely cancer & viral infections, and some specific genetic diseases, namely muscular dystrophy & cystic fibrosis.

Numerous factors are propelling the global gene therapy market growth. These factors, as per the new MRFR report, comprise increasing funds for gene therapy research, availability of favourable reimbursements, increasing cases of cancer & other target diseases, and strategic collaborations & product launches made by key players for staying ahead in the competition. Besides, rising cases of target diseases, large investments made by top market players, and robust product pipeline are also adding gene therapy market growth.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8399

On the contrary, strict regulatory policies coupled with high product development cost are factors that may deter the gene therapy market growth over the forecast period as per the gene therapy market forecast.

Gene Therapy Market Segmentation

The global gene therapy market has been segmented based on indication, product, and end user.

By product, the gene therapy market is segmented into yescarta, zynteglo, luxturna, imlygic, kymriah, zolgensma, strimvelis, and others.

By indication, the gene therapy market is segmented into oncology, genetic disorders/diseases, and others. Among these, the oncology segment will have a major share in the market over the forecast period. The robust cancer gene therapy pipeline, coupled with surging cancer cases, is adding to the growth of the segment.

By end user, the gene therapy market is segmented into hospitals and clinics, the specialty treatment centre, & others. Among these, hospitals & clinics will lead the market over the forecast period. The burgeoning number of hospitals, coupled with hospitals & clinics being the foremost choice to treat diseases, is boosting the growth of this segment.

Gene Therapy Market Regional Analysis

Based on the region, the global gene therapy market report covers the recent trends and growth opportunities across Europe, North America, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, North America will have lions share in the market over the forecast period for the rising cases of chronic diseases, increasing healthcare expenditure, advanced & innovative healthcare infrastructure, presence of eminent market players, and availability of favorable reimbursements.

The global gene therapy market in Europe is predicted to have favorable growth over the forecast period for industry players coming up with innovative product launches, top companies in the region extending product distribution by securing approval from various regulatory bodies, and increasing expenditure for gene and cell therapy companies in the UK.

The global gene therapy in the Asia Pacific region is likely to grow at a fast pace during the forecast period. The rising government initiatives for the healthcare sector development, presence of top market players in the region, launch & approval of various gene therapy products, rising prevalence of chronic diseases, and growing awareness about gene therapy are adding market growth.

The global gene therapy market in the Middle East and Africa is predicted to hold the smallest share over the forecast period for restricted healthcare infrastructure in the region.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/gene-therapy-market-839

Gene Therapy Market Key Players

Eminent players in the global gene therapy market include Orchard Therapeutics plc (UK), Novartis AG (Switzerland), Lonza (Switzerland), CEVEC (Germany), Amgen, Inc. (US), Gilead Sciences, Inc. (US), Thermo Fisher Scientific Inc. (US), Spark Therapeutics, Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US),and uniQure N.V (Netherlands).

Table Of Contents

Chapter 1. Report Prologue

Chapter 2. Gene Therapy Market Introduction

Definition

Scope Of The Study

Research Objective

Assumptions

Limitations

Chapter 3. Research Methodology

Introduction

Primary Research

Secondary Research

Market Size Estimation

Chapter 4. Gene Therapy Market Dynamics

Drivers

Restrains

Opportunities

Challenges

TOC Continued

Browse More Healthcare Research Reports at:

Intraoperative Neurophysiological Monitoring Market Trends, Size and Application, By Type (EEG, EMG and Evoked Potential (EP)), Method (Invasive, Non-Invasive and Minimally Invasive), Source (In-house, Outsource and Tele-Health), Procedure (Spinal, Neurovascular, Orthopedic, Otolaryngology Surgery, Urology and others) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast to 2027 https://www.marketresearchfuture.com/reports/intraoperative-neurophysiological-monitoring-market-729

Healthcare IoT Security Market Research Report: Information by Component (Solution and Services), Solutions Type (Analytics, Encryption, Data Loss Protection, Identity and Access Management and Unified Threat Management), Service Type (Consulting Services, Risk Assessment Services, Design & Integration Services and Managed Security Services), Security Type (Application, Cloud, Endpoint and Network), Application (Pharmaceutical, Medical Devices and Biotechnology) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 https://www.marketresearchfuture.com/reports/healthcare-iot-security-market-946

Ultra-low Temperature Freezers Market: Information by Type (Upright, Chest), Degree of Cooling (-41C to -86 C Freezers, -87C to -150 C Freezers), Application (Blood & Blood Products, Biological Samples, Drug Compounds, Others), End-User (Bio-Banks, Hospitals & Clinics, Academic & Research Laboratories, Others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027 https://www.marketresearchfuture.com/reports/ultra-low-temperature-freezer-market-1813

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Here is the original post:
Gene Therapy Market Size Is Expected to Grow at a CAGR of 40.7% By 2025 | Share Analysis, Growth Outlook, COVID-19 Impact and Size Estimation -...

Choroideremia Treatment Market Business Growth by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc – 3rd Watch News

By adminJuly 17, 2020Gene Therapy Clinics

Data Bridge Market Researchhas added an exhaustive research study of theGlobal Choroideremia Treatment Marketdetailing every single market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The research report presents a complete assessment of the market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

Global Choroideremia Treatment Marketis expected to grow at a steady CAGR in the forecast period of 2019-2026.Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Global Choroideremia Treatment Market By Treatment Type (Gene Therapy, Surgery), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Forecast to 2026

Download exclusive PDF sample report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-choroideremia-treatment-market

Some of the major competitors currently working in the global choroideremia treatment market areBiogen, 4D Molecular Therapeutics, Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant AG, F. Hoffmann-La Roche Ltd and others.

Market Definition:

Choroideremia is also known as choroidal sclerosis is a rare, degenerative, X-linked inherited retinal disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina due to Mutations in the CHM gene. This CHM gene required to produce Rab escort protein-1 (REP-1). The condition gets its name from the distinctive sweet odor of affected infants urine and is also c, a protein that takes part in targeting vesicles (small sacs of substances) into, out of, and within cells.

According to the statistics published by U.S. Department of Health & Human Services, an estimated population of choroideremia is about 1 in 50,000-100,000 people. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Segmentation:Global Choroideremia Treatment Market

By Treatment

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Download Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-choroideremia-treatment-market

Key Developments in the Market:

Competitive Analysis:

Global choroideremia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global choroideremia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Order a Copy of Global Choroideremia Treatment Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-choroideremia-treatment-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

View original post here:
Choroideremia Treatment Market Business Growth by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc - 3rd Watch News

These were the worst performing ASX 200 shares last week – Motley Fool Australia

By adminJuly 17, 2020Stem Cell Medicine

Motley Fool Australia Share Fallers These were the worst performing ASX 200 shares last week

James Mickleboro | July 18, 2020 8:46am | More on: AVH MP1 MSB PNV ASX 200

The S&P/ASX 200 Index(ASX: XJO) was back on form last week and stormed through the 6,000 points level once again. The benchmark index climbed 1.9% to 6033.6 points.

Unfortunately, not all shares were able to climb higher with the market. Heres why these were the worst performing ASX 200 shares last week:

TheAVITA Therapeutics Inc(ASX: AVH)share price was the worst performer on the ASX 200 last week and crashed 19% lower. This follows the release of the regenerative medicine companys fourth quarter and full yearsales update. For FY 2020, AVITAs total revenue came in at approximately US$14.32 million. While this was a sizeable increase of US$8.78 million or 160% over FY 2019s sales, it appears as though investors were expecting an even stronger sales result.

TheMesoblast limited(ASX: MSB) share price was some way behind with a 9.5% decline last week. This appears to have been driven by profit taking after some very strong gains. In fact, a week earlier the allogeneic cellular medicines developers shares were among the best performers. Investors were fighting to buy shares after it provided an updateon its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L. That update revealed that remestemcel-L has been given an expanded access protocol for compassionate use in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome.

ThePolyNovo Ltd(ASX: PNV)share price was out of form last week and tumbled 7% lower. Once again, this appears to have been down to profit taking after strong gains in previous months. For example, even after last weeks declines, PolyNovos shares are still up over 35% since the start of the year.

The Megaport Ltd (ASX: MP1) share price was a poor performer last week and recorded a 6.9% decline. It appears as though investors were rotating funds out of the tech sector over the period. The provider of elastic interconnection services across data centres wasnt the only tech share taking a tumble. The S&P/ASX 200 Information Technology index ran out of steam last week and fell 3.5% despite the ASX 200 pushing 1.9% higher.

5 stocks under $5

We hear it over and over from investors, "I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I'd be sitting on a gold mine!" And it's true.

And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

See the 5 stocks

*Extreme Opportunities returns as of June 5th 2020

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited, MEGAPORT FPO, and POLYNOVO FPO. The Motley Fool Australia has recommended Avita Medical Limited and MEGAPORT FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

James Mickleboro has been a Motley Fool contributor since late 2015. After studying economics at university back home in the United Kingdom, James came to live in Australia and managed to land a job at an Australian fund manager. This was the start of a love affair with Australian equities and he hasnt looked back since. James is part of the CFA Institutes Chartered Financial Analyst program and hopes it teaches him how to become an astute investor which allows him to help others with their own investing. Outside of reading and researching he spends many a late night watching the English Premier League and Seinfeld reruns.

Visit link:
These were the worst performing ASX 200 shares last week - Motley Fool Australia

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab – Business Wire

By adminJuly 17, 2020Stem Cell Clinic

SOMERSET, N.J. & BURLINGAME, Calif.--(BUSINESS WIRE)--Catalent and Humanigen, Inc. (HGEN) (Humanigen) today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigens proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies and consumer health products. Humanigen is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys lead therapeutic candidate.

Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical COVID-19 pneumonia, the majority of whom showed rapid recovery and hospital discharge. A Phase 3 study is currently underway evaluating hospitalized COVID-19 patients.

Based on lenzilumabs promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab, commented Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen. If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most.

Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials, commented Karen Flynn, President of Catalent Biologics and Chief Commercial Officer. The experience we already have with lenzilumab, and our OneBio integrated offering from development to supply, make Catalent uniquely suited to support Humanigen in the journey to make this promising therapy available to COVID-19 patients as soon as possible following receipt of regulatory approvals.

To date, Catalent Biologics has provided early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, Wisconsin to support Humanigens ongoing clinical trials across various disease categories. Under the expanded partnership, Catalent is also providing clinical supply support for Humanigens Phase 3 potential registration study in COVID-19 from its Philadelphia facility.

Lenzilumab was originally manufactured in Catalents Madison facility using Catalent Biologics proprietary GPEx cell line development technology. As part of the expanded partnership, Catalent intends to provide additional drug substance clinical supply for Humanigens clinical trials, Expanded Access Program (EAP), as well as additional late-stage development and clinical and potential commercial drug substance manufacturing and vial filling at its Madison and Bloomington, Indiana, sites.

Catalent Biologics Madison facility provides development and drug substance manufacturing, including GPEx cell line development, process development, process validation, formulation development, and clinical and commercial cGMP manufacturing. Its Bloomington facility has deep expertise in sterile formulation, with drug substance development and manufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges as well as primary and secondary packaging.

Catalents OneBio Suite is an integrated solution for the development, manufacturing, and supply of biologic drugs. Launched in May 2019, the suite of offerings is designed to integrate activities and accelerate timelines, reduce risk and simplify development with a single contract, program manager, and development timeline from cell line development to supply, with harmonized quality systems.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

About Catalent Biologics

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.

Humanigens Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

Here is the original post:
Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab - Business Wire